Cognigenics is a privately held pre-clinical neuro-engineering company pioneering the frontier of RNA based therapeutics and focused on developing and commercializing innovative genetic medicines to treat a range of important neurodegenerative disorders including anxiety, Mild Cognitive Impairment, Alzheimer’s disease and cognitive decline. Delivered intranasally and using CRISPR and RNAi gene editing techniques, efficacy and specificity with no off-target effects have been shown in multiple animal studies. The technology supports the company’s current two compounds, and can be a platform for multiple therapeutics. The company is currently working toward filing an IND and is seeking financing and collaboration opportunities to advance its compounds.